Cyrus Therapeutics Inc.
June 17, 2025
Company Presentation
Oncology
153B
Cyrus Therapeutics Inc. is a clinical trial-ready stage biotechnology company focused on discovering and developing innovative medicines to address chronic or life-threatening diseases with significant unmet medical needs.
Our lead program, CYRS1542 (GSPT1 Molecular Glue Degrader, US IND No.: 174397) , is being developed for indications including neuroendocrine cancers such as small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC), and neuroendocrine prostate cancer (NEPC), as well as metastatic castration-resistant prostate cancer (mCRPC).
Key Highlights of CYRS1542:
• Potent and orally bioavailable:
• Optimized degradation kinetics: Demonstrates a wider therapeutic window
• Efficacy and tolerability: Dose-dependent, durable anti-tumor efficacy with good tolerability
• Robust safety profile: Completion of a 4-week GLP toxicity study in monkeys
• Regulatory progress: IND applications are approved in the U.S. in April 30 and Korea in May 2025.
Company HQ City:
Seoul
Company HQ State:
Seoul
Company HQ Country:
Korea, Republic of
Year Founded:
Complete Series B
Lead Product in Development:
US IND-Approved (No. 174397) GSPT1 Molecular Glue Degrader, CYRS1542
CEO
Byong Moon Kim, PhD
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
2
When you expect your next catalyst update?
Phase1 clinical study of CYRS1542
What is your next catalyst (value inflection) update?
within 18 months
Website
https://www.cyrustx.com
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}